Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Mapi Pharma granted United States patent covering glatiramer depot for multiple sclerosis
Long term follow up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia.
Minocycline treatment for rheumatoid arthritis: an open dose finding study.
Santhera receives first product approval: Health Canada approves Catena® for treatment of Friedreich's ataxia
Early signs of memory impairment among multiple sclerosis patients with clinically isolated syndrome.
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Treatment selection and experience in multiple sclerosis: survey of neurologists.
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit
Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis.
Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1-images in multiple sclerosis.
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
Food and Drug Administration briefing document for ofatumumab
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
Topical Application of Fingolimod Perturbs Cutaneous Inflammation.
Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS.
Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Transcriptomics: mRNA and alternative splicing.
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis

Pages